Table 4.
Adjusted tertiles of IGF-1 and IGFBPs in BO cases compared with GORD controls, screening colonoscopy controls and matched colonoscopy control subset: analyses adjusted for age, gender, race (Caucasian vs other) and waist-to-hip ratio
| Tertiles
| ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | p Value* | 1 | 2 | 3 | p Value* | 1 | 2 | 3 | p Value* | |
| BO cases vs GORD controls | BO cases vs screening colonoscopy controls | BO cases vs matched colonoscopy controls | ||||||||||
| IGF-1 | ||||||||||||
| Range, ng/ml | <155 | 155–211 | >211 | 0.10 | <94.4 | 94.4–130.9 | >130.9 | <0.001 | <95.3 | 95.3–133.1 | >133.1 | <0.0001 |
| Cases | 74 | 28 | 31 | 33 | 24 | 76 | 10 | 17 | 52 | |||
| Controls | 49 | 42 | 44 | 311 | 310 | 311 | 61 | 60 | 61 | |||
| OR (95% CI) | 1.0 (referent) | 0.5 (0.25 to 1.05) | 0.57 (0.27 to 1.17) | 1.0 (referent) | 1.77 (0.81 to 3.88) | 4.05 (2.01 to 8.17) | 1.0 (referent) | 2.21 (0.87 to 5.56) | 5.83 (2.54 to 13.36) | |||
| IGFBP-1 | ||||||||||||
| Range, ng/ml | <4.54 | 4.54–14.9 | >14.9 | 0.94 | <13.2 | 13.9–31.5 | >31.5 | <0.001 | <13.8 | 13.8–29.3 | >29.3 | <0.0001 |
| Cases | 45 | 47 | 41 | 91 | 32 | 10 | 49 | 23 | 8 | |||
| Controls | 49 | 42 | 44 | 318 | 306 | 308 | 60 | 61 | 60 | |||
| OR (95% CI) | 1.0 (referent) | 1.12 (0.57 to 2.44) | 1.04 (0.49 to 2.16) | 1.0 (referent) | 0.34 (0.19 to 0.61) | 0.11 (0.05 to 0.24) | 1.0 (referent) | 0.47 (0.24 to 0.91) | 0.17 (0.07 to 0.43) | |||
| IGFBP-3 | ||||||||||||
| Range, ng/ml | <3327 | 3327–3977 | >3977 | 0.02 | <3286 | 3286–4020 | >4020 | <0.001 | <3001 | 3001–3908 | >3908 | 0.05 |
| Cases | 81 | 36 | 16 | 81 | 36 | 16 | 30 | 35 | 15 | |||
| Controls | 48 | 42 | 45 | 313 | 309 | 310 | 61 | 60 | 61 | |||
| OR (95% CI) | 1.0 (referent) | 0.77 (0.38 to 1.57) | 0.36 (0.16 to 0.81) | 1.0 (referent) | 0.92 (0.52 to 1.61) | 0.40 (0.20 to 0.79) | 1.0 (referent) | 1.04 (0.54 to 2.00) | 0.45 (0.20 to 0.98) | |||
| Molar† | ||||||||||||
| Range | <0.15 | 0.15–0.21 | >0.21 | 0.34 | <0.104 | 0.104–0.119 | >0.119 | <0.001 | <0.106 | 0.106–0.135 | >0.135 | <0.0001 |
| Cases | 51 | 43 | 39 | 30 | 8 | 95 | 6 | 11 | 61 | |||
| Controls | 55 | 40 | 40 | 351 | 194 | 387 | 61 | 60 | 61 | |||
| OR (95% CI) | 1.0 (referent) | 1.71 (0.84 to 3.44) | 1.41 (0.68 to 2.94) | 1.0 (referent) | 0.90 (0.31 to 2.52) | 4.72 (2.24 to 9.92) | 1.0 (referent) | 2.36 (0.76 to 7.32) | 16.82 (5.71 to 49.5) | |||
*
p Value denotes trend across tertiles.
†
Molar represents molar ratio of IGF-1 to IGFBP-3.
BO, Barrett’s oesophagus; GORD, gastro-oesophageal reflux disease; IGF-1, insulin growth factor 1; IGFBP-1, IGFBP-3, IGF binding proteins 1 and 3.